NEWS / ARTICLES
NEWS RELEASES
  • October 21, 2019
    MTI Secures $4.2M Financing Round
    MTI announced a $4.2M raise. The company's lead product, PolypDx™, is the world's first and only urine test for colorectal cancer screening. Developed in Canada, and patented globally, PolypDx™ is currently being assessed by the Alberta provincial health system in Canada as a way to increase overall screening efforts to help manage the disease of colorectal cancer. The next critical step to bring MTI's innovative test to patients, is a multi-centre pivotal trial in the US. Evidence generated from the trial will provide the basis for a commercial launch, clinical acceptance and reminbursement of PolypDx™.
  • September 25, 2019
    MTI Named BioAlberta Company of the Year
    MTI was presented with the BioAlberta Company of the Year Award at the 20th Annual BioAlberta Awards Gala last night. This Award was presented to MTI for excellence and innovation with their flagship product, PolypDx™,  and their strong performance and leadership role in the Alberta business community. MTI was presented the award by Bob Dawson, Senior Manager, Patient Access and Health Policy, from Pfizer Canada.
  • May 27, 2019
    DynaLIFE Accelerator Lab welcomes new partner and leading-edge cancer screening technology in Edmonton
    DynaLIFE and Metabolomic Technologies Inc. (MTI) today unveiled a new state-of-the-art clinical space in Edmonton enabling the assessment of an innovative new test for Albertans in the detection and prevention of colorectal cancer, the second most commonly diagnosed cancer in Canada and the second and third leading cause of cancer-related deaths for men and women. "Over the past few months, DynaLIFE has been working closely with MTI and their flagship product, PolypDx™ with the aim to provide doctors with this exceptional new tool for early screening and detection enabling the timely removal of polyps before they progress to colorectal cancer," says Jason Pincock, Chief Executive Officer of DynaLIFE. "Partnering with MTI was a natural fit for DynaLIFE as we immediately recognized the value of incorporating this innovative diagnostic technology."
  • October 22, 2018
    Alberta to assess a new screening strategy using MTI's PolypDx™
    Metabolomic Technologies Inc. (MTI) today announced the launch of a $1.4 million project that will evaluate a new colorectal cancer screening strategy using PolypDx™, the first and only urine test for the detection and prevention of colorectal cancer. The project, called the Canadian Assessment of PolypDx™ (CAP), will engage expert physicians, clinicians, patients and laboratory specialists to assess colorectal cancer screening in 3000 patients in five regions located throughout Alberta.
  • October 7-10, 2018
    MTI to Exhibit at ACG - October 7-10 in Philadelphia
    MTI is excited to be attending the 2018 American College of Gastroenterology Conference in Philadelphia, PA. Team members will be on site ready to discuss the first and only urine test for detection and prevention of colorectal cancer, PolypDx™. Come check us out at Booth #1237 in the Exhibit Hall!
  • November 8, 2017
    MTI selected to present at Falling Walls Venture in Berlin, Germany
    Metabolomic Technologies Inc. is selected as one of 20 outstanding science based start-ups from leading international academic institutions and international venture capitalists in the Falling Walls Venture competition held in Berlin, Germany. As a finalist for the competition, Dr. Chang presented MTI's easy-to-use test for the screening and prevention of colorectal cancer to a gathering of science based start-ups, investors and opinion leaders at the British Embassy in Berlin.
  • November 3, 2017
    MTI Receives ASTech Outstanding Leadership in Technology Award
    Metabolomic Technologies Inc. is the 2017 recipient of the Outstanding Leadership in Technology Award from the ASTech Foundation. The ASTech Foundation award recognizes outstanding innovation in science and technology in Alberta.
  • November 1, 2017
    Patent Granted for PolypDx™ in Europe
    Metabolomic Technologies Inc. has been granted a patent for its PolypDx™ technology by the European Patent Office. PolypDx™ received patent approval in Japan in September, 2015, and in Australia in February, 2017. Patents are also pending in the US, Canada and Hong Kong.
  • June 21, 2017
    MTI Appoints David Chang as New CEO
    Metabolomic Technologies Inc. announces that it has appointed David Chang as Chief Executive Officer as of May 1st, 2017. Dr. Chang replaces Reg Joseph as CEO. He brings to the position 15 years experience managing SMEs and commercializing research projects. As the previous Chief Operating Officer of MTI, Dr. Chang oversaw the development of PolypDx™ from the research lab to market, and has established MTI as a respected and award-winning innovator.
  • June 6, 2017
    MTI Recipient of the 2017 ATB Catalyst Export Award
    On June 6, 2017 MTI was presented with the 2017 ATB Catalyst Export Award. The award recognizes MTI's engagement in international business and export, while achieving excellence through sustainable growth and innovation.
  • May 5, 2017
    MTI Launches New Product Website - PolypDx.com
    MTI is pleased to announce the launch of a new product website for our flagship product, PolypDx™. This website will provide important education and information on PolypDx™ for both patients and healthcare professionals, as we expand coverage of PolypDx™ in the US and worldwide.
  • May 6 to 9, 2017
    MTI to Exhibit at DDW - May 2017 in Chicago, IL
    MTI is excited to be attending the 2017 Digestive Disease Week Conference, May, 2017 in Chicago, IL. Team members will be on site ready to discuss our non-invasive urine-based diagnostic test for detection of adenomatous polyps, PolypDx™. Come check us out at Booth #1612 in the New Exhibitor Pavillion Area! 
  • March 25, 2017
    MTI's Chief Operating Officer, Dr. David Chang - 2017 Canadian Medtech Mission to China
    From March 20 to 23, 2017, MTI's Dr. David Chang travelled to Beijing and Tianjin, China, as part of a delegation of medical device companies from Canada. PolypDx™ was featured as a leading potential diagnostic for the Chinese market. The Canadian mission was highlighted in this Beijing news piece on March 23, 2017 - Canadian Medical Companies Visit Beijing.
  • February 9, 2017
    MTI Granted Patent for PolypDx™ in Australia
    In early February, 2017, Metabolomic Technologies Inc. was granted a patent for its PolypDx™ technology by the Australian Patent Office. PolypDx™ received patent approval in Japan in September, 2015. Patents are also pending in the US, Canada, and Europe.
  • January 23, 2017
    MTI Signs Muti-Year, Non-Exclusive Licensing and Distribution Agreement with U.S. Based Evolution Laboratories in Association with Lab Express, LLC 
    MTI has signed a multi-year, non-exclusive licensing and distribution agreement with U.S. based Evolution Laboratories for its flagship product, PolypDx™, a urine-based diagnostic test for detection of adenomatous polyps, the precursor to colorectal cancer. This agreement marks the second licensing and distribution secured by MTI in the last year. The non-exclusive licensing and distribution agreement signed between MTI and Evolution Laboratories in association with Lab Express, LLC, provides additional entry points into five western U.S. states including; Nevada, California, Arizona, Utah and Texas. 
  • June 27, 2016
    Atlantic Diagnostic Laboratories Launches Revolutionary Urine-Based Diagnostic Test to Detect Precursor to Colon Cancer
    Atlantic Diagnostic Laboratories (ADL), today announced the official launch of PolypDx™, a non-invasive urine-based diagnostic test for detection of adenomatous polyps, the precurser to colorectal cancer. "ADL, with it's extensive LC/MS/MS expertise, is very excited to be offering the PolypDx™ non-invasive urine test for its official launch into America," said Aaron Domenico, Chief Operating Officer of ADL. "Colorectal cancer is a leading cause of death in the United States. With early detection in the adenamatous polyp stage, this form of cancer is preventable."